India's Strides Pharma jumps on successful closure of USFDA inspection at Bengaluru facility
BUZZ-India's Strides Pharma jumps on successful closure of USFDA inspection at Bengaluru facility ** Pharmaceutical company Strides Pharma Science's shares SRID.NS rise as much as 10.29%, biggest single-day jump in about seven months, to 1056 rupees apiece; last up 4.7%
** Uptick after SRID says its flagship manufacturing facility in Bengaluru received the Establishment Inspection Report (EIR) from the U.S. drug regulator, indicating successful closure of inspection at the facility
** U.S. Food and Drug Administration (USFDA) had conducted a good manufacturing practices inspection from May 12 to May 20, and issued a Form 483 with five observations
** Current closure of the inspection comes after SRID addressed all the observations by the USFDA within the stipulated timeline
** Stock is most active in seven months, with trading volume of 2584,969 shares as of 11:03 a.m. IST, 10.2x the 30-day average, according to data compiled by LSEG
** SRID shares are up 10.7% in 2026 so far
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
Recent news on Strides Pharma Science
See all newsIndia's Strides Pharma jumps on successful closure of USFDA inspection at Bengaluru facility
Brief: Strides Pharma Science Receives USFDA EIR For Flagship Facility In Bengaluru
Brief: Strides Pharma Science Receives US FDA Establishment Inspection Report For Bengaluru Facility
Brief: Strides Pharma Science June-Quarter Consol Net Profit 1.57 Billion Rupees
Brief: Strides Pharma Science March-Quarter Consol Net Profit 1.27 Billion Rupees